IGF1 and osteosarcoma: Since the effects of stimulation or inhibition of the TGF-β pathway on osteosarcoma cell proliferation is debatable [9], and the developed TGF- β pathway inhibiting agents elicit unwanted effects [13], we will focus on the possibility of targeting the IGF pathway in osteosarcoma.